Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

CD8 < sup>+ T cells in the cancer-immunity cycle. Immunity 2023, 56(10):2231–2253.

Betof Warner A, Hamid O, Komanduri K, Amaria R, Butler MO, Haanen J, Nikiforow S, Puzanov I, Sarnaik A, Bishop MR et al. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy. J Immunother Cancer 2024, 12(2).

Zhu M, Huang Y, Bender ME, Girard L, Kollipara R, Eglenen-Polat B, Naito Y, Savage TK, Huffman KE, Koyama S, et al. Evasion of Innate Immunity contributes to small cell Lung Cancer Progression and Metastasis. Cancer Res. 2021;81(7):1813–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Xu J, Wu X, Yao H, Yan Z, Guo T, Wang W, Wang P, Li Y, Yang X, et al. CD147 regulates antitumor CD8 + T-cell responses to facilitate tumor-immune escape. Cell Mol Immunol. 2021;18(8):1995–2009.

Article  CAS  PubMed  Google Scholar 

The Lancet O. CAR T-cell therapy for solid tumours. Lancet Oncol. 2021;22(7):893.

Article  Google Scholar 

Vesely MD, Zhang T, Chen L. Resistance mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45–74.

Article  CAS  PubMed  Google Scholar 

Simmons K, Kee BK, Raghav KPS, Johnson B, Kopetz S, Willis J, Dasari A, Sanchez EV, Ludford K, Parseghian CM, et al. Clinical outcomes following termination of immunotherapy due to long-term benefit in MSI-H colorectal cancer. J Clin Oncol. 2022;40(16suppl):3585–3585.

Article  Google Scholar 

Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S et al. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 2021, 9(7).

Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥ 2 immune-related adverse events in patients with cancer. J Immunother Cancer 2020, 8(2).

Khan AB, Carpenter B, Santos ESP, Pospori C, Khorshed R, Griffin J, Velica P, Zech M, Ghorashian S, Forrest C, et al. Redirection to the bone marrow improves T cell persistence and antitumor functions. J Clin Invest. 2018;128(5):2010–24.

Article  PubMed  PubMed Central  Google Scholar 

Ma J, Liu Y, Duan C, Wu S, Xie Y, Yang L, Li X, Wang Y, Zhang Y, Zhuang R. CD226 knockout reduces the development of CD8 + T by impairing the TCR sensitivity of double-positive thymocytes. Immunology. 2023;169(1):83–95.

Article  CAS  PubMed  Google Scholar 

Baumgaertner P, Schmidt J, Costa-Nunes CM, Bordry N, Guillaume P, Luescher I, Speiser DE, Rufer N, Hebeisen M. CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity. Front Immunol. 2022;13:973986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schöllhorn A, Maia A, Kimmerle F, Born J, Rammensee HG, Dimitrov S, Gouttefangeas C. Staining of activated ß(2)-integrins in combination with CD137 and CD154 for sensitive identification of functional antigen-specific CD4(+) and CD8(+) T cells. Front Immunol. 2022;13:1107366.

Article  PubMed  Google Scholar 

Schmidt J, Chiffelle J, Perez MAS, Magnin M, Bobisse S, Arnaud M, Genolet R, Cesbron J, Barras D, Navarro Rodrigo B, et al. Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors. Nat Commun. 2023;14(1):3188.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Watson NB, Patel RK, Kean C, Veazey J, Oyesola OO, Laniewski N, Grenier JK, Wang J, Tabilas C, Yee Mon KJ, et al. The gene regulatory basis of bystander activation in CD8 < sup>+ T cells. Sci Immunol. 2024;9(92):eadf8776.

Article  CAS  PubMed  Google Scholar 

Fu W, Lei C, Liu S, Cui Y, Wang C, Qian K, Li T, Shen Y, Fan X, Lin F, et al. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun. 2019;10(1):4355.

Article  PubMed  PubMed Central  Google Scholar 

Seo N, Shirakura Y, Tahara Y, Momose F, Harada N, Ikeda H, Akiyoshi K, Shiku H. Activated CD8 + T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. Nat Commun. 2018;9(1):435.

Article  PubMed  PubMed Central  Google Scholar 

Upadhyay R, Boiarsky JA, Pantsulaia G, Svensson-Arvelund J, Lin MJ, Wroblewska A, Bhalla S, Scholler N, Bot A, Rossi JM, et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 2021;11(3):599–613.

Article  CAS  PubMed  Google Scholar 

Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y, Wang Y, Li D, Liu W, Zhang Y et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 2020, 368(6494).

Zhang Z, Zhang Y, Xia S, Kong Q, Li S, Liu X, Junqueira C, Meza-Sosa KF, Mok TMY, Ansara J, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, Zhao J, Liu J, Lu Y, Xing Y, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. 2018;19(10):1112–25.

Article  CAS  PubMed  Google Scholar 

He TS, Ji W, Zhang J, Lu J, Liu X. ALG-2 couples T cell activation and apoptosis by regulating proteasome activity and influencing MCL1 stability. Cell Death Dis. 2020;11(1):5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robinson GL, Dinsdale D, Macfarlane M, Cain K. Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAIL. Oncogene. 2012;31(48):4996–5006.

Article  CAS  PubMed  Google Scholar 

Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495–506.

Article  CAS  PubMed  Google Scholar 

Zeng X, Liao G, Li S, Liu H, Zhao X, Li S, Lei K, Zhu S, Chen Z, Zhao Y, et al. Eliminating METTL1-mediated accumulation of PMN-MDSCs prevents hepatocellular carcinoma recurrence after radiofrequency ablation. Hepatology. 2023;77(4):1122–38.

Article  PubMed  Google Scholar 

Carleton G, Lum JJ. Autophagy metabolically suppresses CD8(+) T cell antitumor immunity. Autophagy. 2019;15(9):1648–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

MacNabb BW, Chen X, Tumuluru S, Godfrey J, Kasal DN, Yu J, Jongsma MLM, Spaapen RM, Kline DE, Kline J. Dendritic cells can prime anti-tumor CD8(+) T cell responses through major histocompatibility complex cross-dressing. Immunity. 2022;55(11):2206–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cho H, Binder J, Weeratna R, Dermyer M, Dai S, Boccia A, Li W, Li S, Jooss K, Merson J, et al. Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens. Cancer Immunol Immunother. 2023;72(2):287–300.

Article  CAS  PubMed  Google Scholar 

Lerner EC, Woroniecka KI, D’Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, Waibl-Polania J, Wachsmuth LP, Miggelbrink AM, Jackson JD, et al. CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis. Nat Cancer. 2023;4(9):1258–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, Birkbak NJ, Veeriah S, Van Loo P, Herrero J, et al. Allele-specific HLA loss and Immune escape in Lung Cancer Evolution. Cell. 2017;171(6):1259–e12711211.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yajima T, Nishimura H, Wajjwalku W, Harada M, Kuwano H, Yoshikai Y. Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response. Int J Cancer. 2002;99(4):573–8.

Article  CAS  PubMed  Google Scholar 

Cheng YC, Ku WC, Tseng TT, Wu CP, Li M, Lee SC. Anchorage independence altered vasculogenic phenotype of melanoma cells through downregulation in aminopeptidase N /syndecan-1/integrin β4 axis. Aging. 2020;12(17):16803–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, et al. Sialic Acid Blockade suppresses Tumor Growth by enhancing T-cell–mediated tumor immunity. Cancer Res. 2018;78(13):3574.

Article  PubMed  Google Scholar 

Büll C, Boltje TJ, Balneger N, Weischer SM, Wassink M, van Gemst JJ, Bloemendal VR, Boon L, van der Vlag J, Heise T, et al. Sialic Acid Blockade suppresses Tumor Growth by enhancing T-cell-mediated tumor immunity. Cancer Res. 2018;78(13):3574–88.

Article  PubMed  Google Scholar 

Li X-Y, Moesta AK, Xiao C, Nakamura K, Casey M, Zhang H, Madore J, Lepletier A, Aguilera AR, Sundarrajan A, et al. Targeting CD39 in Cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 2019;9(12):1754–73.

Article  CAS  PubMed